コーパス検索結果 (right1)
通し番号をクリックするとPubMedの該当ページを表示します
2 al Performance Test score increased more in the combination group than in the aerobic and resistance groups (27.9 to 33.4
3 ractures was lower by 19% in the romosozumab-to-alendronate group than in the alendronate-to-alendronate group (178 of 20
4 on cancer risk was higher in the proinflammatory-change DII group than in the antiinflammatory-stable DII group (hazard r
5 nt initiation were significantly higher in the blinatumomab group than in the chemotherapy group, both with respect to co
7 24 months), mortality was lower in the HVPG-guided therapy group than in the control group (29% vs. 43%; hazard ratio [H
8 -ART initiation was significantly lower in the intervention group than in the control group (31 [33%] of 94 participants
9 ession-free survival were significantly longer in the study group than in the control group (both were 28 months vs 10 mo
10 elihood of event-free survival was higher in the nusinersen group than in the control group (hazard ratio for death or th
11 likelihood of overall survival was higher in the nusinersen group than in the control group (hazard ratio for death, 0.37
12 overall survival was significantly longer in the cetuximab group than in the control group (HR 0.58, 95% CI 0.36-0.86; p
13 rsion in liquid media was faster in the 35 mg/kg rifampicin group than in the control group (median 48 days vs 62 days, a
14 l, we identified more infections (n = 146) in the denosumab group than in the control group (n = 99).
15 nt lunch order were significantly lower in the intervention group than in the control group at follow-up.
16 ignificantly higher percentage of infants in the nusinersen group than in the control group had a motor-milestone respons
17 ignificantly higher percentage of infants in the nusinersen group than in the control group had a motor-milestone respons
18 the superficial capillary plexus was lower in the amblyopic group than in the control group in both 3 x 3-mm and 6 x 6-mm
19 rations were persistently lower in the sacubitril/valsartan group than in the enalapril group over the 3-year follow-up (
20 3]; p<0.0001) were significantly higher in the EUC plus CAP group than in the EUC alone group, but we noted no effect on
21 FeFum+NaFeEDTA compared with FeSO4 was higher in the Fe+GOS group than in the Fe group (88% compared with 63%; P = 0.006)
22 There were more reports of diarrhea in the iron complex group than in the ferrous sulfate group (58% vs 35%, respecti
23 chopathologic findings were significantly higher in the CBT group than in the GSH-I group at 6-month follow-up (adjusted
26 On Day 2, PaO2/FiO2 ratio was higher in the sevoflurane group than in the midazolam group (mean +/- SD, 205 +/- 56 vs
27 sion-free survival was 2.7 months longer in the combination group than in the monotherapy group: 4.2 months versus 1.5 mo
28 The rate of VOCE was higher in the positive mismatch group than in the negative mismatch group (hazard ratio, 0.38
29 es, and relative to the pretreatment period) in SLIT tablet group than in the non-AIT group (P<.001).
30 tal deaths were significantly higher in the hypoalbuminemic group than in the non-hypoalbuminemic group (6.6% vs 3.1%, P
31 ntly more restrictive (lower median CCS) in the hemorrhagic group than in the nonhemorrhagic group (1 vs 6.5; P < .001).
32 more severe dysfunction) was greater in the angiotensin II group than in the placebo group (-1.75 vs. -1.28, P=0.01).
33 njection-site reactions were more common in the bococizumab group than in the placebo group (10.4% vs. 1.3%, P<0.001).
34 ia, which occurred in fewer participants in the liraglutide group than in the placebo group (161 vs. 215 patients; hazard
35 ade 3-4 neutropenia was more frequent in the co-trimoxazole group than in the placebo group (8.1% vs 5.8%, p=0.03).
36 3 mg per deciliter (1.12 mmol per liter) in the anacetrapib group than in the placebo group (a relative difference of 104
37 s also significantly greater weight loss in the liraglutide group than in the placebo group (at 5 weeks: median 3.7 kg [I
38 ge in ACQ7 greater in the extrafine inhaled corticosteroids group than in the placebo group (difference between groups 0.
39 verall survival was significantly longer in the midostaurin group than in the placebo group (hazard ratio for death, 0.78
40 y (n=196) was significantly lower in the pooled canakinumab group than in the placebo group (p=0.0007 for trend across gr
41 iltration rate increased (P=0.003) more in the elamipretide group than in the placebo group (P=0.11).
42 rse events that occurred more frequently in the cannabidiol group than in the placebo group included diarrhea, vomiting,
43 l attendance with exacerbations was 27% lower in the active group than in the placebo group, but this did not reach signi
49 ommittee found a higher number of deaths in the rilotumumab group than in the placebo group; all patients in the rilotumu
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。